Category Archives: Diagnosis

Mobile suitcase laboratory: A tool for the rapid detection of emerging and endemic infectious disease

Ahmed Abd El Wahed who is based at Georg-August University, Goettingen, Germany shares his experiences with development and use of field diagnostics that can fit in a suitcase. This work received support from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland. He explains the concept here …

Laboratory diagnosis mainly depends on nucleic acid detection by real-time polymerase chain reaction (PCR), which is available in central laboratories and has a turnaround time of more than two hours. Since real-time RT-PCR assays are not suitable for on-site screening, samples collected from local hospitals, treatment center or at the site of an outbreak have to be sent to laboratories over long distances for testing.

In developing countries, the necessary equipment for diagnosis is only available in few central laboratories, which are not accessible and of limited capacity to test large numbers of incoming samples. Moreover, transport conditions of samples are inadequate and therefore lead to unreliable results.

lab-in-a-suitcaseFor decentralizing of the molecular diagnostics, there is a need for a simple molecular point-of-need test. We have developed a mobile suitcase laboratory (62+49+30 cm) containing all reagents and equipment for the detection of the nucleic acid of infectious agents using the recombinase polymerase amplification (RPA) technology. The RPA assay run at a constant temperature (42°C) for a maximum of 15 minutes.

Moreover, all reagents are cold-chain independent and the mobile laboratory is operated by a solar power battery. The nucleic acid extraction is performed by a magnetic bead based method, in which a simple fast lysis protocol is applied. In case of highly infectious agents such as Ebola virus, the inactivation step was performed in a glovebox.

The suitcase lab is designed to detect almost 30 pathogens such as Dengue, Zika, Chikungunya, Ebola, Coronaviruses as well as Tuberculosis, Leptospira, Salmonella typhi and paratyphi, malaria, avian influenza, and Leishmania.

The suitcase lab featured in a presentation at the 65th Annual Meeting of the American Society of Tropical Medicine in Atlanta under the title of “Novel Extraction Protocol and Recombinase Polymerase Amplification Assay for Detection of Leishmania Donovani In 30 Minutes.” Authors/presenters included Dinesh Mondal, Prakash Ghosh, Md. Anik Ashfaq Khan, Faria Hossain, Susanne Böhlken-Fascher, Greg Matlashewski, Axel Kroeger, Piero Olliaro, and Ahmed Abd El Wahed.

Their work highlighted Leishmania donovani (LD), a protozoan parasite transmitted to humans by sand flies, which causes Visceral Leishmaniasis (VL). Currently, diagnosis is based on presence of anti-LD antibodies and clinical symptoms. Molecular diagnosis would require real-time PCR, which is not easy to implement at field settings.

In this study, we report on the development and testing of a novel extraction protocol in combination with recombinase polymerase amplification (RPA) assay for the detection of LD. The LD RPA assay detected equivalent to one LD genomic DNA. The RPA assay was performed at constant temperature (42°C) and the total assay runtime including the extraction procedure was 30 minutes.

The RPA assay also detected other Leishmania species (L. major, L. aethiopica and L. infantum), but did not identify nucleic acid of other pathogens. Forty-eight samples from VL, asymptomatic and post-kala-azar dermal leishmaniasis subjects were detected positive and 48 LD negative samples were negative by both LD RPA and real-time PCR assays, which indicates 100% agreement.

To allow the use of the assay at field settings, a mobile suitcase laboratory (56+45.5+26.5 cm) was developed and operated at the local hospital in Mymensingh, Bangladesh by using a solar-powered battery. DNA extraction was performed by a novel magnetic bead based method, in which a simple fast lysis protocol was applied.

Towards Malaria Pre-Elimination in Rwanda: Active Case Investigation in a Low Endemic District

A poster entitled “Towards Malaria Pre-Elimination in Rwanda: Active Case Investigation in a Low Endemic District” was presented by members of Jhpiego’s Rwanda Team and colleagues:

Noella Umulisa, Angelique Mugirente, Veneranda Umubyeyi, Beata Mukarugwiro, Stephen Mutwiwa, Jean Pierre Habimana, and Corrine Karema, at the 65th annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta. The abstract follows …

case-detectionRwanda has seen an increase in malaria cases recently with an increase from 514,173 cases in 2012 to 1,957,402 cases in 2015. This change can be attributed to an increase in temperature, rainfall, and resistance to insecticides.

Despite this setback, Rwanda is aiming to reach the pre-elimination phase by 2018. In January 2015, 11 health facilities in Rubavu, a low endemic district, started implementing reactive active case detection after training 55 health care providers and 11 lab technicians on the topic. This strategy involves screening and treating individuals living in close proximity to passively detected cases, also known as index cases. Index cases can be used to identify population groups that are sources of infection.

cases-confirmed-investigatedFrom January 2015 to December 2015, 16,434 cases of Malaria were detected and treated at 11 health facilities in Rubavu District. Among these cases, 2,917(17.8%) index cases were investigated and 4,943 individuals (between 1 and 2 contacts for each index case) living in proximity of index cases were tested using rapid diagnostic tests by health care providers. Of these, 508 (10.3%) tested positive for malaria and were treated according to national guidelines.

These data shows that the number of investigated cases is still lower than the national guidelines of screening 5 individuals residing between 100 to 500 meters of every confirmed case. This low rate could be due to the increase of malaria cases in Rwanda which has placed a burden on health care providers and health facilities in areas like Rubavu which used to be low endemic malaria areas. Additionally, data gathered through supervision activities has indicated a need for additional training on screening investigations in order to adhere to national guidelines and conduct the investigations more efficiently.

Active case investigation could be improved by training and involving more health care providers such as community health workers who could reduce the burden on health center staff. The additional support for case investigation activities and improved training can help to achieve higher coverage of individuals located near index cases.

A Pilot to Use Malaria RDTs at the Community Level in Burkina Faso

A poster entitled “The Improving Malaria Care (IMC) Project’s Contribution to follow up a Pilot to Use Rapid Diagnostic Tests (RDTs) at the Community Level in Burkina Faso” was presented by members of Jhpiego’s Burkina Faso Team: Ousmane Badolo, Stanislas P. Nebie, Moumouni Bonkoungou, Mathurin Dodo, Rachel Waxman, Danielle Burke, William Brieger at the 65th annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta. The abstract follows …

CHWs provide malaria testing, treatment and health education

CHWs provide malaria testing, treatment and health education

Early and correct case management of malaria in health facilities and at the community level is among the priorities of Burkina Faso’s National Malaria Control Program (NMCP). In line with this initiative, the NMCP piloted use of Rapid Diagnostic Tests (RDTs) by Community Health Workers (CHWs) to confirm malaria cases in the three health districts of Kaya, Saponé and Nouna between 2013 and 2015. With PMI support, follow-up visits were organized to document best practices, as well as challenges, on RDT use by CHWs that could serve as lessons learned for scale-up.

During follow-up visits, malaria commodities management (supply, storage and use) at the community level was examined, use of RDTs was assessed, and implementation at the community stockoutlevel was discussed with all actors at regional, district, health facilities, and community levels. The team examined the monitoring/supervision processes at all levels, used a check list on malaria commodities management, and employed a questionnaire for each type of actor. Both qualitative and quantitative data have been collected. A total of 108 persons were contacted including 32 CHWs, 42 community leaders and 34 health care providers and managers.

chw-drug-kitFindings revealed frequent stock-outs of RDTs and artemisinin-based combination therapies, non-payment of stipends to CHWs (a demotivator) and insufficient supervision of CHW by health teams. From the community perspective, 66% of community leaders were satisfied with their CHW’s work (diagnosis and treatment of uncomplicated malaria concernsand referral of severe cases to health facilities). However, 46% of community leaders complained of frequent stock-outs and unanimously agreed on the importance of regular payment of premiums to CHW.

Follow up of the pilot was valuable in obtaining community, CHW and health worker perspectives for improving the program. While the community finds the program acceptable, its sustainability will require that solutions be found for stock-outs, non-payment, and insufficient supervision before scale up takes place.

Urine Rapid Diagnostic Test for Malaria: Results Published

Results of testing the innovative Urine Rapid Diagnostic Test for Malaria developed by Fyodor Biotech have been published in the Journal of Clinical Microbiology. Authors from multiple collaborating institutions include Wellington A. Oyibo, Nnenna Ezeigwe, Godwin Ntadom, Oladipo O. Oladosu, Kaitlin Rainwater, Wendy O’Meara, Evaezi Okpokoro, and William Brieger. The abstract appears below.

fydor_0 Background: The need to expand malaria diagnosis alongside policy requirements for mandatory testing before treatment motivates exploration of non-invasive rapid diagnostic tests (RDTs). We report the outcome of the first cross-sectional, single-blind clinical performance evaluation of a Urine Malaria Test (UMT) for Plasmodium falciparum (Pf) malaria diagnosis in febrile patients.

Methods: Matched urine and fingerprick blood from participants ?2 years with fever (axillary temperature ?37.5°C) or history of fever in the preceding 48 hours were tested with UMT and microscopy (as gold standard). BinaxNOW® (Pf/Pan) blood RDT was done to assess relative performance. Urinalysis and Rheumatoid Factor (RF) tests were conducted to evaluate possible interference. Diagnostic performance characteristics were computed at 95% CI.

UNT is winner of innovations prize

UMT is winner of innovations prize

Results: Of 1,800 participants screened, 1,691 were enrolled; 566 (34%) were febrile, 1,125 (66%) afebrile; test positivity among enrolled participants: 341 (20%) by microscopy, 419 (25%) UMT, 676 (40%) BinaxNow Pf and 368 (22%) BinaxNow Pan. UMT sensitivity among febrile patients (for whom the test is indicated) was 85% and specificity 84%. Among febrile children ?5 years, UMT sensitivity was 93%, specificity 83%. Area under receiver-operator characteristic curve (AUC) of UMT (0.84) was not significantly different from Binax Pf (0.86) or Binax Pan (0.87), indicating that the tests do not differ in overall performance. Gender, seasons, and RF did not impact UMT performance. Leukocytes, hematuria and urobilinogen concentration in urine were associated with lower UMT specificity.

Conclusion: UMT performance was comparable to BinaxNOW Pf/Pan tests, and is a promising tool to expand malaria testing in public and private healthcare settings where there are challenges to blood-based malaria diagnosis testing.

Community health workers provide integrated community case management using malaria rapid diagnostic test kits

Please find below the abstract of the above named article that is first appearing as an accepted paper in the journal Research in Social and Administrative Pharmacy. The authors – Bright C. Orji, Namratha Rao, Elizabeth Thompson, William R. Brieger, Emmanuel
‘Dipo Otolorin – conducted this work as part of Jhpiego’s commitment to fighting malaria in Nigeria.

ABSTRACT

Background: Throughout Nigeria malaria is an endemic disease. Efforts to treat malaria can also be combined with other illnesses including pneumonia and diarrhea, which are killing children under five years of age. The use of Rapid Diagnostic Test (RDT) aids early  diagnosis of malaria and informs when other illnesses should be considered. Those with positive RDT results should be treated with Artemisinin-based Combination Therapy (ACTs), while those with negative RDTs results are further investigated for pneumonia and diarrhea.

Community Directed Distributor performs malaria rapid diagnostic test of febrile child

Community Directed Distributor performs malaria rapid diagnostic test of febrile child

Critical health systems challenges such as human resource constraints mean that community case management (CCM) and community health workers such as volunteers called Community Directed Distributors (CDDs) can therefore play an important role in diagnosing and treating malaria. This report described an effort to monitor and document the performance of trained CDDs in providing quality management of febrile illnesses including the use of RDTs.

Method: The program trained one hundred and fifty-two (152) CDDs on the use of RDTs to test for malaria and give ACTs for positive RDTs results, cotrimoxazole for the treatment of pneumonia and Oral rehydration solution and zinc for diarrhea They were also taught to counsel on compliance medicine, identify adverse reactions, and keep accurate records. The CDDs worked for 12 Calendar months. Their registers were retrieved and audited using a checklist to document client complaints, tests done, test results and treatment provided. No client identifying information was collected.

Results: There were 32 (21%) male CDDs and 120 (79%) females. The overall mean age of the CDDs was 36.8 (±8.7) years old. 89% of the male CDDs provided correct treatment based on RDT results compared to 97.6% of the female CDDs, a statistically significant difference. Likewise CDDs younger than 36 years of age provided 92.7% correct case management compared to those 36 years and older (98.4%). The difference between the age groups was also significant. There was a strong association between CDDs dispensing ACTs with positive RDT results. In RDT negative cases, the most common course of action was dispensing antibiotics (43.2%), followed by referring the patients (30.34%) and the providing ORS (24.1%).

Conclusion: Volunteer CDDs who are community members can adhere to treatment protocols and guidelines and comply with performance standards. The next step is scaling this approach to a state-wide level.

Accepted Date: 26 September 2016. Please cite this article as: Orji BC, Rao N, Thompson E, Brieger WR, ‘Dipo Otolorin E, Community health workers provide integrated community case management using malaria rapid diagnostic test kits, Research in Social & Administrative Pharmacy (2016), doi: 10.1016/j.sapharm.2016.09.006.

Disrupting Malaria: How Fyodor Biotechnologies is changing the diagnostics game

Efosa Ojomo, Senior Researcher, Harvard Business School, Forum for Growth and Innovation looks at the new innovation award recipient, the designers of the Urine Malaria Test, and explains how the technology disrupts the system that has made it difficult to reach the average malaria sufferer with appropriate diagnostics and treatment.

In 2015, 214 million people were infected with malaria, 190 million of whom were in African countries. Of those infected, 438,000 died, 91% of who were in Africa. In addition, malaria has significant financial implications on families, companies and countries. Experts estimate that in countries burdened with malaria, the disease is responsible for as much as 40% of public health expenditures, 30 to 50% of in-patient hospital visits, and 50% of out-patient visits.

From a financial standpoint, direct costs of managing the disease is up to $12 billion annually, while the cost in lost economic growth is many times more. Considering the scale of malaria’s impact on Africa, there have been many innovations that have helped curb the spread of the disease, but perhaps one of the most significant is Fyodor Biotechnology’s disruptive Urine Malaria Test (UMT).

UMT-DiagThe UMT, a Significant Malaria Milestone

Fyodor’s UMT is a simple urine test where patients simply pee on a stick in order to find out whether they have malaria. The World Health Organization states that “Early diagnosis and treatment of malaria reduces disease and prevents deaths. Access to diagnostic testing and treatment should be seen… as a fundamental right of all populations at risk.” In other words, if we diagnose early, we will save many more lives and limit transmission.

fyodortableUMT is an inexpensive (introductory price: ~$2 per test to end user) malaria diagnostic test that does not require the expertise of a trained professional. The UMT kit also does not require a lab or special disposal due to its simplicity. It is a three step process that lets patients know, in 20 minutes, if they have malaria.

Why the UMT is Disruptive

The most important hallmark of a disruptive innovation is that it makes complicated and expensive products simple and affordable, enabling many more people in society to benefit from the innovation. The UMT fits this model as the differences between the UMT and existing blood-testing kit below clearly illustrate.

One of the most exciting things about the UMT is Dr. Agbo’s goal to manufacture the product in Africa. “With an investment of $5 million, we can build a fully equipped manufacturing plant in Nigeria. That amount will only get us a building in the United States,” he explained.

Innovation Prize of Africa winners IPA2016winners-1200x590 at Forbes2It is solutions like these that African investors and policy makers need to support in order to get Africa on a path to sustainable economic development. As reported by Forbes, the UMT is an innovative product by Africans for Africans. This is why the UMT is an innovation winner.

(A longer version of this posting appeared on the World Bank Africa Can blog.)

We cannot end malaria for good without addressing flaviviruses

“End malaria for good”, the theme for the 2016 World Malaria Day, presents us with a double challenge.  We want to end malaria finally, or eliminate it between 2030 and 2040, but also, ending it will be good for saving lives and improving economies of endemic countries. The challenge arises when we consider whether we will have adequate resources to accomplish the task. As colleagues from the University of California in San Francisco observed, “Sustaining domestic and international funding as malaria burden decreases is a serious concern for most of the eliminating countries.”

One way to guarantee resources is through conserving what we have and only treating people for malaria when they actually have the disease and not some other febrile illness. The advent of malaria rapid diagnostic tests (mRDTs) that can be used at the primary care level, including within the community should have improved our ability to differentiate malaria from other causes of fever.  Unfortunately mRDTs do not always guide correct case management.  When a febrile patient tests negative, we may not have the ability to do further differential diagnosis. Some causes of fever do not have a direct cure. Therefore if malaria drugs are available through programs like the Global Fund, we are tempted to use them since many front line clinicians feel that, “We must do something for the patient.”

?

?

Flaviviruses pose one challenge. Such choices not only waste scarce resources but may be harmful. A prime example is the recent outbreak of Yellow Fever in Angola. According to the World Health Organization, “The first, ‘acute’, phase usually causes fever, muscle pain with prominent backache, headache, shivers, loss of appetite, and nausea or vomiting,” making it easily confused with malaria. Treating most of these patients with malaria drugs may not cause harm, but 15% go on to develop severe disease including hemorrhaging and death. Proper use of mRDTs, follow-up observation of RDT-negative patients and provision of supportive care that treats dehydration, respiratory failure, and fever, can save lives.

Rapid diagnostic test kits are widely used in India for the diagnosis of dengue infection,  but do not feature in African clinics. Without Dengue RDTs, clinicians in Africa may assume that Dengue is a severe form of malaria and treat as malaria even without parasitological laboratory evidence. With suspected Dengue patients increased intake of oral fluids is recommended by WHO along with paracetamol (not aspirin) for fever and pains.

So far the global Zika Virus outbreak has spared Africa of its worst neurological and brain damaging effects. For the current epidemic the U.S. Centers for Disease Control and Prevention inform that, “The most common symptoms of Zika also resemble malaria and are fever, rash, joint pain, or conjunctivitis (red eyes). Other common symptoms include muscle pain and headache.”  for which CDC recommends palliative case management.

Like other flaviviruses Chikungunya “causes fever and severe joint pain. Other symptoms include muscle pain, headache, nausea, fatigue and rash,” according to WHO. WHO explains that, “Most patients recover fully, but in some cases joint pain may persist for several months, or even years.

It will be good to end malaria for good, but we must also have the means to detect and manage the other dangerous, life threatening febrile diseases that will be left behind. In the meantime we need to conduct proper differential diagnosis starting with mRDTs so that expensive malaria medicines will be used judiciously and correctly and other febrile illnesses will receive appropriate life-saving care.

Lassa Fever in Nigeria

Fever brings to mind ‘malaria’ for most health workers often resulting in dangerous nmis-diagnoses. Not all fevers are alike, and when health workers do not practice infection procedures in examining a febrile patient, they put themselves, their families and all people at their clinic at risk.

lassa-distribution-map smWitness the Ebola outbreak in Guinea, Liberia and Sierra Leone where health workers disproportionately died. And just as happened with Ebola, the Guardian reported that, “A medical doctor in Rivers State has been confirmed dead after being diagnosed of See WHO’s Lassa fever fact sheetin the state’s apex hospital, the Brewaithe Memorial Specialist Hospital (BMH), Port Harcourt.”

As of 9th January the death toll rose to 35 with 81 cases. The Guardian Newspaper noted that “Non-Specific Symptoms Of Ailment Threaten Interruption Efforts, ” and that at the rate the current Lassa Fever outbreak is ravaging in the country, the federal government may soon have no option but to declare an emergency to hasten containment.”

By January 16th the number of deaths had risen to 44 as reported by MENAFN.com. They also explained that Lassa is “transmitted through the faeces, urine and blood of rats (and subsequently) human bodily fluids,” of those infected via rats. Rats closely inhabit spaces with humans, while fruit bats that carry Ebola are more confined to forests (which unfortunately have been pushed back through human activity).

Lassa is endemic in Nigeria and West Africa across to Liberia, Sierra Leone and Guinea where some suspected the initial Ebola cases might have been Lassa. The first cases were CDC: documented in Nigeria in 1969, and as the AllAfrica.Com, Guardian: Ministry of Health noted, “Lassa fever which has over the years registered its presence in the country, supposed not to have taken us by surprise.”

The US Centers for Disease Control and Prevention/CDC provides the following useful information showing that while infectious, Lassa may not be as dangerous as Ebola:

  • “Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. For the majority of Lassa fever virus infections (approximately 80%), symptoms are mild and are undiagnosed. Mild symptoms include slight fever, general malaise and weakness, and headache. In 20% of infected individuals, however, disease may progress to more serious symptoms including hemorrhaging (in gums, eyes, or nose, as examples), respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock. Neurological problems have also been described, including hearing loss, tremors, and encephalitis. Death may occur within two weeks after symptom onset due to multi-organ failure.”

7 pricks finger for blood collection 2Finally CDC cautions health workers to protect themselves and not assume every fever is malaria. “When caring for patients with Lassa fever, further transmission of the disease through person-to-person contact or nosocomial routes can be avoided by taking preventive precautions against contact with patient secretions (called VHF isolation precautions or barrier nursing methods). Such precautions include wearing protective clothing, such as masks, gloves, gowns, and goggles; using infection control measures, such as complete equipment sterilization; and isolating infected patients from contact with unprotected persons until the disease has run its course.”

While health workers at the front line are encouraged to use malaria Rapid Diagnostic Tests to determine or exclude a diagnosis of malaria, they must remember that RDTs involve blood. Protective materials are always required, even for ‘simple’ malaria. Health systems – public and private – need to ensure health workers have these life saving materials.

Pneumonia and Malaria – similar challenges and pathways to success

ConcentrationOfPneumoniaDeathsWorld Pneumonia Day (WPD) helps us focus on the major killers of children globally. While Pneumonia is responsible for more child mortality across the world, in tropical malaria endemic areas both create nearly equal damage (see WPD graphic showing Nigeria and DRC which are both have the highest burden for pneumonia, but also malaria). Of particular concern is case management at the clinic and community level where there is great need to differentiate between these two forms of febrile illness so that the right care is given and lives are saved.

WPD_2014_logo_portraitDiagnostics are a particular challenge. While we now have malaria rapid diagnostic test kits that can be used at the community level, we must rely on breath counting for malaria. The Pneumonia Diagnostics Project (see video) “is working to identify the most accurate and acceptable devices for use by frontline health workers in remote settings in Cambodia, Ethiopia, South Sudan and Uganda.”

Ease of use at low cost must be achieved. One approach to solve the pneumonia diagnostics challenge at community and front line clinic level is to find “mobile phone applications or alternative energy for pulse oximetry,” to test low oxygen levels.

PneumoniaCareVaccine development for both diseases is underway. The challenge for malaria results from the different stages of the parasites life-cycle. Lack of affordable vaccines for pneumonia limits at present widespread preventive action, though public-private partnerships offer hope.

Dispersable and correct dose for age prepackaged malaria drugs are already available. Now more child-friendly medicines for pneumonia are being developed. In low resource settings, “amoxicillin dispersible tablets are a better option, particularly for children who can’t swallow pills. They have a longer shelf-life, are cost-effective, don’t need refrigeration, and are easy to administer.”

Similarities in the problems and solutions to control these two diseases require that interventions must continue to be developed and implemented jointly in order to benefit children the most. As can be seen again from the WPD graphics (right), many children do not get needed treatment. Integrated case management at all levels is the answer.

Evaluation of Community Malaria Worker Performance in Western Cambodia: a Quantitative and Qualitative Assessment

Sara E. Canavati de la Torre and colleagues[1] conducted a study of Community health workers who focus on malaria. They are sharing their results with us below.

Village/ Mobile Malaria Workers (VMWs/MMWs) are a critical component in Cambodia’s national strategy to reduce malaria morbidity and mortality. Since Sara map image0162004, VMWs have been providing free malaria diagnosis and treatment using Rapid Diagnostic Tests and Artemisinin-based Combination Therapies in hard-to-reach villages (>5km from closest health facility).

VMWs play a key role in control and prevention, diagnosis and treatment of malaria as well as in delivering behavioral change communication (BCC) interventions to this target population. Out photos shows a village malaria worker at a health center registering number of patients diagnosed and treated during a month.

Sara CHW image013Overall the study aimed to evaluate the implementation of these activities performed by VMW/MMWs, a quantitative and qualitative assessment was conducted in 5 provinces of western Cambodia in order to:

  • understand job satisfaction of VMWs and MMWs vis-a-vis their roles and responsibilities;
  • assess their performance according to their job descriptions;
  • gain insights into the challenges faced in delivery of diagnosis, treatment and health education activities to their communities.

A total of 196 VMWs/MMWs were surveyed in October 2011 using a combination of quantitative and qualitative methods. Triangulation of quantitative and qualitative data helped to gain a deeper understanding of the success factors of this intervention and the challenges faced in implementation. The Map of Provinces shows ODs and HCs visited by the field team in zones 1 and 2 of the containment project.

Sara Results image018The Figure shows that overall, levels of VMW performance were in line with the expected performance (80%) and some were higher than expected. However, some performance gaps were identified in the areas of knowledge of malaria symptoms, treatment regimens, and key messages. In particular, there were low levels of practice of the recommended direct observed therapies (DOTs) approach for malaria treatment (especially for the second and third doses), reportedly caused by stock-outs, distance and transportation.

The national malaria program should aim to focus on improving knowledge of VMWs in order to address misconceptions and barriers to effective implementation of DOTs at community-levels. In addition to the findings, the tools developed, will potentially help the national program to come up with better indicators in the near future.

[1] Sara E. Canavati de la Torre1,2,8 Po Ly2, Chea Nguon3, Arantxa Roca-Feltrer4,9, David Sintasath5, Maxine Whittaker6, Pratap Singhasivanon7 – 1Faculty of Tropical Medicine, Mahidol University/ Malaria Consortium Cambodia, Phnom Penh, Cambodia; 2The National Centre of Parasitology and Malaria Control, Phnom Penh,, Cambodia; 3The National Centre of Parasitology and Malaria Control, Phnom Penh, Cambodia; 4Malaria Consortium Cambodia, Cambodia; 5Malaria Consortium Asia Regional Office, Bangkok, Thailand; 6 Australian Centre for International and Tropical Health, University of Queensland, Queensland, Australia; 7Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 8Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 9London School of Tropical Medicine and Hygiene, London, UK